Regeneron's Pasatru wins FDA approval after trial cut new bone formation for FOP patients

Regeneron Pharmaceuticals won FDA approval for Pasatru to treat fibrodysplasia ossificans progressiva (FOP), marking a rare regulatory success for a medicine aimed at an ultra‑rare disease that causes bone to form in soft tissues. STAT frames the approval as the capstone of roughly three decades of research into FOP and highlights comments from the pivotal trial’s lead investigator, Richard Keen of the Royal National Orthopaedic Hospital in London, who said the treatment 'almost completely stops the new [bone] forming.'

For patients and families living with FOP, the approval represents more than a new drug label: STAT emphasizes the prospect that Pasatru can preserve mobility and potentially extend life. The article foregrounds clinical impact rather than commercial detail, presenting the approval through the testimony of clinicians who led the trial and by characterizing the result as the culmination of long-running scientific effort. STAT’s coverage focuses on clinical outcomes and investigator commentary rather than on regulatory debate or postapproval access. The report does not provide pricing, coverage, or global rollout details; it centers instead on the medical significance of a therapy that appears to dramatically reduce heterotopic ossification in trial participants. In that respect, the piece reads as both scientific milestone and patient‑centered moment. Regulatory approvals for ultra‑rare diseases often hinge on small, carefully designed trials and on surrogate or clinically meaningful endpoints. STAT notes the pivotal trial data via its interview with Richard Keen and frames the approval as the product of an extended research effort; the article does not enumerate trial sizes, specific endpoint measurements, or detailed safety data in its summary. That leaves readers with a clear sense of medical promise but with limited granular data on efficacy and adverse events. The reporting also stops short of exploring next steps in long‑term follow up, real‑world effectiveness, or how health systems will manage access for a condition that affects very few people. STAT’s story privileges the human and clinical significance — the possibility of preserved mobility and longer survival — while leaving questions about pricing, payer coverage, and international availability unanswered. Clinicians and patient advocates will likely view Pasatru’s approval as transformative, but the wider questions that typically follow orphan‑drug approvals remain: how quickly patients will obtain treatment, how broadly insurers will cover it, and what longer‑term safety and durability data will show. STAT’s piece makes clear that, at least from the perspective of investigators and the outlet’s reporting, the drug substantially alters the clinical trajectory for FOP, even as practical and policy details await further reporting.